

# Standard PREanalytical Code Version 3.0

Fay Betsou,<sup>1</sup> Roberto Bilbao,<sup>2</sup> Jamie Case,<sup>3</sup> Rodrigo Chuaqui,<sup>4</sup> Judith Ann Clements,<sup>5</sup> Yvonne De Souza,<sup>6</sup> Annemieke De Wilde,<sup>7</sup> Jörg Geiger,<sup>8</sup> William Grizzle,<sup>9</sup> Fiorella Guadagni,<sup>10</sup> Elaine Gunter,<sup>11</sup> Stacey Heil,<sup>12</sup> Michael Kiehntopf,<sup>13</sup> Iren Koppandi,<sup>14</sup> Sabine Lehmann,<sup>1</sup> Loes Linsen,<sup>15</sup> Jacqueline Mackenzie-Dodds,<sup>16</sup> Rocío Aguilar Quesada,<sup>17</sup> Riad Tebbakha,<sup>18</sup> Teresa Selander,<sup>19</sup> Katheryn Shea,<sup>20</sup> Mark Sobel,<sup>21</sup> Stella Somiari,<sup>22</sup> Demetri Spyropoulos,<sup>23</sup> Mars Stone,<sup>24</sup> Gunnel Tybring,<sup>25</sup> Klara Valyi-Nagy,<sup>26</sup> and Lalita Wadhwa;<sup>27</sup> and the ISBER Biospecimen Science Working Group

**Keywords:** quality assurance, preanalytical variables, biobank, biospecimen science

**Q**UALITY ASSURANCE in biospecimen collection, processing, and storage is the focus of International Best Practices<sup>1</sup> and accreditation standards.<sup>2</sup> Traceability and documentation of the preanalytical phase is part of recently recommended lists of essential biobank datasets.<sup>3,4</sup> The Standard PREanalytical Code (SPREC) was first developed and published by the ISBER Biospecimen Science Working Group in 2009<sup>5</sup>

and was updated in 2012.<sup>6</sup> The SPREC is a seven-element code corresponding to the most critical preanalytical variables of fluid and solid biospecimens. In this short communication, the SPREC version 3.0 is published. It includes more options, based on recent technological developments and on recently acquired knowledge about the critical ranges of preanalytical times, such as tissue ischemia times (Table 1, Table 2).

TABLE 1. PREANALYTICAL VARIABLES, WITH NEW ELEMENTS IN BOLD ITALIC, INCLUDED IN SPREC (7-ELEMENT LONG SPREC), VERSION SPREC 3.0, APPLIED TO FLUID SAMPLES

Type of sample	
Ascites fluid	ASC
Amniotic fluid	AMN
Bronchoalveolar lavage	BAL
Blood (whole)	<b>BLD</b>

(continued)

TABLE 1. (CONTINUED)

Type of sample	
Bone marrow aspirate	<b>BMA</b>
Breast milk	<b>BMK</b>
Buccal cells	<b>BUC</b>
<b><i>Nondensity-gradient-centrifugation-separated</i></b> buffy coat, viable	<b>BUF</b>
<b><i>Nondensity-gradient-centrifugation-separated</i></b> buffy coat, nonviable	BFF

(continued)

<sup>1</sup>Integrated Biobank of Luxembourg, Dudelange, Luxembourg.

<sup>2</sup>Biobanco Vasco, Torre del BEC, Barakaldo-Biskaia, Spain.

<sup>3</sup>Scripps Center for Organ & Cell Transplantation, La Jolla, California.

<sup>4</sup>NCI/NIH, Rockville, Maryland.

<sup>5</sup>Australian Prostate Cancer Bioresource/Queensland University of Technology, Brisbane, Australia.

<sup>6</sup>University of California, San Francisco, San Francisco, California.

<sup>7</sup>Universitair Ziekenhuis Antwerpen, Edegem, Belgium.

<sup>8</sup>Interdisciplinary Bank of Biomaterials and Data Würzburg, Würzburg, Germany.

<sup>9</sup>University of Alabama at Birmingham, Birmingham, Alabama.

<sup>10</sup>Interinstitutional Multidisciplinary Biobank, IRCCS San Raffaele Pisana, Rome, Italy.

<sup>11</sup>Specimen Solutions LLC, Tucker, Georgia.

<sup>12</sup>Coriell Institute for Medical Research, Camden, New Jersey.

<sup>13</sup>Friedrich-Schiller Universität Jena, Jena, Germany.

<sup>14</sup>Cellular Technology Limited, Shaker Heights, Ohio.

<sup>15</sup>Biobank University Hospitals Leuven, Leuven, Belgium.

<sup>16</sup>Natural History Museum, London, United Kingdom.

<sup>17</sup>Biobanco del Sistema Sanitario Publico de Andalucía, Sevilla, Spain.

<sup>18</sup>Tumorothèque de Picardie, Place Victor Pauchet, Amiens, France.

<sup>19</sup>Biospecimen Repository and Processing Lab, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.

<sup>20</sup>Brooks Life Sciences Systems, Indianapolis, Indiana.

<sup>21</sup>ASIP, Rockville, Maryland.

<sup>22</sup>Windber Research Institute, Windber, Pennsylvania.

<sup>23</sup>Medical University of South Carolina, Charleston, South Carolina.

<sup>24</sup>Blood Systems Research Institute, San Francisco, California.

<sup>25</sup>Karolinska Institutet, Stockholm, Sweden.

<sup>26</sup>University of Illinois at Chicago, Chicago, Illinois.

<sup>27</sup>Texas Children's Hospital, Houston, Texas.

TABLE 1. (CONTINUED)

Type of sample	Type of primary container
<b>Density-gradient-centrifugation-separated</b> mononuclear cells, viable	<b>CEL</b>
Fresh cells from nonblood specimen type	<b>CEN</b>
Cells from nonblood specimen type (e.g., ascites, amniotic), viable	<b>CLN</b>
Cord blood	<b>CRD</b>
Cerebrospinal fluid	<b>CSF</b>
<b>Enriched (physicochemically)</b> <b>circulating tumor cells</b>	<b>CTC</b>
Dried whole blood (e.g., Guthrie cards)	<b>DWB</b>
Nasal washing	<b>NAS</b>
<b>Density-gradient-centrifugation-separated</b> mononuclear cells, nonviable	<b>PEL</b>
Cells from nonblood specimen type (e.g., ascites, amniotic), nonviable	<b>PEN</b>
Pleural fluid	<b>PFL</b>
<b>Dental pulp</b>	<b>PLP</b>
Plasma, single spun	<b>PL1</b>
Plasma, double spun	<b>PL2</b>
Red blood cells	<b>RBC</b>
Saliva	<b>SAL</b>
Semen	<b>SEM</b>
Serum	<b>SER</b>
Sputum	<b>SPT</b>
Stool	<b>STL</b>
Synovial fluid	<b>SYN</b>
Tears	<b>TER</b>
24 h urine	<b>U24</b>
Urine, random ("spot")	<b>URN</b>
Urine, first morning	<b>URM</b>
Urine, timed	<b>URT</b>
Other	<b>ZZZ</b>
<b>Type of primary container</b>	
Acid citrate dextrose	<b>ACD</b>
<b>Chemical additives/stabilizers</b>	<b>ADD</b>
Serum tube without clot activator	<b>CAT</b>
Citrate phosphate dextrose	<b>CPD</b>
Cell Preparation Tube <sup>®</sup> citrate	<b>CPT</b>
<b>Cell Preparation Tube heparin</b>	<b>CPH</b>
<b>Aldehyde-based stabilizer for CTCs</b>	<b>CSV</b>
EDTA and gel	<b>EDG</b>
<b>Physical filtration system</b>	<b>FIL</b>
<b>Glass</b>	<b>GLS</b>
Lithium heparin	<b>HEP</b>
Hirudin	<b>HIR</b>
<b>Lithium heparin and rubber plug</b>	<b>LHB</b>
Lithium heparin and gel	<b>LHG</b>
Oragene collection container or equivalent	<b>ORG</b>
<b>Stool collection container</b> <b>with DNA stabilizer</b>	<b>OMN</b>
PAXgene <sup>®</sup> blood RNA <sup>+</sup>	<b>PAX</b>
Potassium EDTA	<b>PED</b>
Polyethylene tube sterile	<b>PET</b>
S8820 protease inhibitor tablets or equivalent	<b>PII</b>
Protease inhibitors	<b>PIX</b>
Polypropylene tube sterile	<b>PPS</b>
PAXgene blood DNA	<b>PXD</b>
PAXgene bone marrow RNA	<b>PXR</b>
<b>RNA Later<sup>®</sup></b>	<b>RNL</b>
Sodium citrate	<b>SCI</b>

(continued)

TABLE 1. (CONTINUED)

Type of primary container		
<b>Nonaldehyde-based stabilizer</b> <b>for cell-free nucleic acids</b>		<b>SCK</b>
Sodium EDTA		<b>SED</b>
Sodium heparin		<b>SHP</b>
Sodium fluoride/potassium oxalate		<b>SPO</b>
Serum separator tube with clot activator		<b>SST</b>
Tempus <sup>®</sup> tube		<b>TEM</b>
Trace elements tube		<b>TRC</b>
Unknown		<b>XXX</b>
Other		<b>ZZZ</b>
<b>Precentrifugation (delay between</b> <b>collection and processing)</b>		
<b>RT</b>	<b>&lt;30 min</b>	<b>AI</b>
<b>2°C–10°C</b>	<b>&lt;30 min</b>	<b>BI</b>
RT	<2 h	A
2°C–10°C	<2 h	B
RT	2–4 h	C
2°C–10°C	2–4 h	D
RT	4–8 h	E
2°C–10°C	4–8 h	F
RT	8–12 h	G
2°C–10°C	8–12 h	H
RT	12–24 h	I
2°C–10°C	12–24 h	J
RT	24–48 h	K
2°C–10°C	24–48 h	L
RT	>48 h	M
2°C–10°C	>48 h	N
>35°C	<2 h	O
Unknown		X
Other		Z
<b>Centrifugation</b>		
RT 10–15 min	<3000 g no braking	A
RT 10–15 min	<3000 g with braking	B
2°C–10°C 10–15 min	<3000 g no braking	C
2°C–10°C 10–15 min	<3000 g with braking	D
RT 10–15 min	3000–6000 g with braking	E
2°C–10°C 10–15 min	3000–6000 g with braking	F
RT 10–15 min	6000–10000 g with braking	G
2°C–10°C 10–15 min	6000–10000 g with braking	H
RT 10–15 min	>10000 g with braking	I
2°C–10°C 10–15 min	>10000 g with braking	J
RT 30 min	<1000 g no braking	M
No centrifugation		N
Unknown		X
Other		Z
<b>Second centrifugation</b>		
RT 10–15 min	<3000 g no braking	A
RT 10–15 min	<3000 g with braking	B
2°C–10°C 10–15 min	<3000 g no braking	C
2°C–10°C 10–15 min	<3000 g with braking	D
RT 10–15 min	3000–6000 g with braking	E
2°C–10°C 10–15 min	3000–6000 g with braking	F
RT 10–15 min	6000–10000 g with braking	G
2°C–10°C 10–15 min	6000–10000 g with braking	H
RT 10–15 min	>10000 g with braking	I
2°C–10°C 10–15 min	>10000 g with braking	J
No centrifugation		N

(continued)

TABLE 1. (CONTINUED)

<i>Second centrifugation</i>		
Unknown		X
Other		Z
<i>Postcentrifugation delay</i>		
<1 h 2°C–10°C		A
<1 h RT		B
1–2 h 2°C–10°C		C
1–2 h RT		D
2–8 h 2°C–10°C		E
2–8 h RT		F
8–24 h 2°C–10°C		G
8–24 h RT		H
24–48 h 2°C–10°C		I
24–48 h RT		J
<b>&gt;48 h RT</b>		<b>M</b>
Not applicable		N
Unknown		X
Other		Z
<i>Long-term storage</i>		
PP tube 0.5–2 mL	(–85) to (–60)°C	A
PP tube 0.5–2 mL	(–35) to (–18)°C	B
PP tube 0.5–2 mL	<–135°C <sup>a</sup>	V
Cryotube <sup>b</sup> 1–2 mL	LN	C
Cryotube <sup>b</sup> 1–2 mL	(–85) to (–60)°C	D
Cryotube <sup>b</sup> 1–2 mL	Programmable freezing to <–135°C	E
Plastic cryo straw	LN	F
Straw	(–85) to (–60)°C	G
Straw	(–35) to (–18)°C	H
Straw	Programmable freezing to <–135°C	I
PP tube ≥5 mL	(–85) to (–60)°C	J
PP tube ≥5 mL	(–35) to (–18)°C	K
Microplate well	(–85) to (–60)°C	L
Microplate well	(–35) to (–18)°C	M
Cryotube <sup>b</sup> 1–2 mL	LN after temporary (–85) to (–60)°C	N
Plastic cryo straw	LN after temporary (–85) to (–60)°C	O
Paraffin block	RT or 2–10°C	P
<b>Paraffin block</b>	<b>(–35) to (–18)°C</b>	<b>U</b>
Bag	LN	Q
Dry technology medium	RT	R
PP tube 40–500 µL	(–85) to (–60)°C	S
PP tube 40–500 µL	(–35) to (–18)°C	T
PP tube 40–500 µL	<–135°C <sup>a</sup>	W
Original primary container	(–35) to (–18)°C or (–85) to (–60)°C	Y
Unknown		X
Other		Z

Codes in bold come from the LDMS. Volumes refer to container size.

<sup>a</sup>Temperature <–135°C may correspond to LN vapor phase or to –150°C electrical freezer.

<sup>b</sup>Cryotube is defined as a tube that can be stored in LN either vapor or liquid phase.

LDMS, Laboratory Data Management System; h, hour; LN, liquid nitrogen, referring to either vapor or liquid phase (this specific information should be documented in the biobank's SOPs); min, minute; PP, polypropylene; RT, room temperature: 18°C–28°C; SOPs, standard operating procedures.

TABLE 2. PREANALYTICAL VARIABLES, WITH NEW ELEMENTS IN BOLD ITALIC, INCLUDED IN THE SPREC (7-ELEMENT LONG SPREC), VERSION SPREC 3.0, APPLIED TO SOLID SAMPLES

<i>Type of sample</i>	
<b>Bone</b>	<b>BON</b>
Fresh cells from nonblood specimen type (e.g., biopsy)	<b>CEN</b>
Cells from nonblood specimen type (e.g., dissociated tissue), viable	<b>CLN</b>
Cells from fine needle aspirate	FNA
Hair	<b>HAR</b>
Cells from laser capture microdissected tissue	LCM
<b>Nails</b>	<b>NAL</b>
Cells from nonblood specimen type (e.g., dissociated tissue), nonviable	<b>PEN</b>
Placenta	<b>PLC</b>
Solid tissue	<b>TIS</b>
Disrupted tissue, nonviable	TCM
<b>Teeth</b>	<b>TTH</b>
Other	<b>ZZZ</b>
<i>Type of collection</i>	
Autopsy <6 h postmortem	A06
Autopsy 6–12 h postmortem	A12
Autopsy 12–24 h postmortem	A24
Autopsy 24–48 h postmortem	A48
Autopsy 48–72 h postmortem	A72
Biopsy in culture media	BCM
Biopsy	<b>BPS</b>
Biopsy in normal saline or phosphate buffered saline	BSL
Biopsy in tissue low-temperature transport media	BTM
Fine needle aspirate	FNA
Puncture	PUN
Surgical excision in culture media	SCM
Surgical excision	SRG
Surgical excision in normal saline or phosphate buffered saline	SSL
Surgical excision in tissue low-temperature transport media	STM
Surgical excision in vacuum container	VAC
Swab	<b>SWB</b>
Other	<b>ZZZ</b>
<i>Warm ischemia time</i>	
<2 min	A
2–10 min	B
10–20 min	C
20–30 min	D
30–60 min	E
>60 min	F
Unknown	X
Not applicable (e.g., biopsy)	N
Other	Z
<i>Cold ischemia time</i>	
<b>RT</b> <2 min	A
<b>RT</b> 2–10 min	B
<b>RT</b> 10–20 min	C
<b>RT</b> 20–30 min	D
<b>RT</b> 30–60 min	E

(continued)

TABLE 2. (CONTINUED)

<i>Cold ischemia time</i>		
<b>RT 60 min–3 h</b>	<b>F</b>	
<b>RT 3 h–6 h</b>	<b>G</b>	
<b>RT 6 h–12 h</b>	<b>H</b>	
<b>RT &gt;12 h</b>	<b>I</b>	
<b>2°C–10°C &lt;60 min</b>	<b>E4</b>	
<b>2°C–10°C 60 min–3 h</b>	<b>F4</b>	
<b>2°C–10°C 3–6 h</b>	<b>G4</b>	
<b>2°C–10°C 6–12 h</b>	<b>H4</b>	
<b>2°C–10°C &gt;12 h</b>	<b>I4</b>	
Unknown	X	
Not applicable (e.g., autopsy)	N	
Other	Z	
<i>Fixation/stabilization type</i>		
Nonaldehyde with acetic acid	ACA	
Aldehyde based	ALD	
Allprotect® tissue reagent	ALL	
Alcohol based	ETH	
Nonbuffered formalin	FOR	
Heat stabilization	HST	
Snap freezing	SNP	
Nonaldehyde based without acetic acid	NAA	
Neutral buffered formalin	NBF	
Optimum cutting temperature medium	OCT	
PAXgene tissue	PXT	
RNA Later	RNL	
<b>Vacuum technology stabilization</b>	<b>VAC</b>	
Unknown	XXX	
Other	ZZZ	
<i>Fixation time</i>		
<15 min	A	
15 min–1 h	B	
1–4 h	C	
4–8 h	D	
8–24 h	E	
24–48 h	F	
48–72 h	G	
<b>&gt;72 h</b>	<b>H</b>	
Not applicable	N	
Unknown	X	
Other	Z	
<i>Long-term storage</i>		
PP tube 0.5–2 mL	(–85) to (–60)°C	A
PP tube 0.5–2 mL	(–35) to (–18)°C	B
PP tube 0.5–2 mL	<–135°C <sup>a</sup>	V
Cryotube <sup>b</sup> 1–2 mL	LN	C
Cryotube <sup>b</sup> 1–2 mL	(–85) to (–60)°C	D
Cryotube <sup>b</sup> 1–2 mL	Programmable freezing to <–135°C	E
Plastic cryo straw	LN	F
Straw	(–85) to (–60)°C	G
Straw	(–35) to (–18)°C	H
Straw	Programmable freezing to <–135°C	I
PP tube ≥5 mL	(–85) to (–60)°C	J
PP tube ≥5 mL	(–35) to (–18)°C	K
Microplate well	(–85) to (–60)°C	L
Microplate well	(–35) to (–18)°C	M
Cryotube <sup>b</sup> 1–2 mL	LN after temporary (–85) to (–60)°C	N

(continued)

TABLE 2. (CONTINUED)

<i>Long-term storage</i>		
Straw	LN after temporary (–85) to (–60)°C	O
Paraffin block	RT or 2 to 10°C	P
<b>Paraffin block</b>	<b>(–35) to (–18)°C</b>	<b>U</b>
Bag	LN	Q
Dry technology medium	RT	R
PP tube 40–500 µL	(–85) to (–60)°C	S
PP tube 40–500 µL	(–35) to (–18)°C	T
PP tube 40–500 µL	<–135°C <sup>a</sup>	W
Original primary container	(–35) to (–18)°C or (–85) to (–60)°C	Y
Unknown		X
Other		Z

Codes in bold come from the LDMS. Volumes refer to container size.

<sup>a</sup>Temperature <–135°C may correspond to LN vapor phase or to –150°C electrical freezer.

<sup>b</sup>Cryotube is defined as a tube that can be stored in LN, either vapor or liquid phase.

LN, Liquid nitrogen refers to either vapor or liquid phase (this specific information should be documented in the biobank's SOPs); PP, polypropylene; RT, room temperature: 18°C–28°C.

### Author Disclosure Statement

No competing financial interests exist.

### References

- 2012 ISBER Best Practices for repositories collection, storage, retrieval, and distribution of biological materials for research international society for biological and environmental repositories. *Biopreserv Biobank* 2012;10:79–161.
- ISO/DIS 20387:2017(E) Biotechnology–Biobanking–General requirements for biobanks. <https://www.iso.org/standard/67888.html>.
- Moore HM, Kelly A, Jewell SD, et al. Biospecimen reporting for improved study quality. *Biopreserv Biobank* 2011;9:57–70.
- Roxana M-M, Loreana N, van Enkevort D, et al. Toward global biobank integration by implementation of the minimum information about biobank data sharing (MIABIS 2.0 Core). *Biopreserv Biobank* 2016;14:298–306.
- Betsou F, Lehmann S, Ashton G, et al. Standard preanalytical coding for biospecimens: Defining the sample PREanalytical code. *Cancer Epidemiol Biomarkers Prev* 2010;19:1004–1011.
- Lehmann S, Guadagni F, Moore H, et al. Standard preanalytical coding for biospecimens: Review and implementation of the Sample PREanalytical Code (SPREC). *Biopreserv Biobank* 2012;10:366–374.

Address correspondence to:

Fay Betsou, PhD, HDR  
 Integrated Biobank of Luxembourg  
 1 rue Louis Rech  
 Dudelange L-3555  
 Luxembourg

E-mail: fay.betsou@ibbl.lu